Akoya Biosciences on Monday announced the launch of its PhenoCode Signature Panels for high-throughput spatial biomarker discovery and validation on the firm's PhenoImager platforms.
The PhenoCode Signature Panels are a hybrid of the company’s legacy Codex and Opal assays, and, when combined with the PhenoImager platforms, enable spatial phenotyping workflow, Akoya said.
Each panel includes markers for phenotyping the tumor microenvironment and immune status, the company added.
“The rapidly expanding immuno-oncology therapeutic and clinical trial landscape is necessitating the need for more predictive tissue-based biomarker solutions,” Brian McKelligon, CEO of Akoya, said in a statement. “The PhenoCode Signature Panels provide our translational and clinical partners with a ready-made and customizable solution to rapidly advance their biomarker programs.”
Akoya will present posters describing the use of the PhenoCode Signature Panels at the Society for Immunotherapy of Cancer (SITC) 47th Annual Meeting held in Boston from November 8 to November 12.
